Core Insights - Esperion announced the acceptance of two abstracts for presentation at the American College of Cardiology's 2026 Annual Scientific Session, focusing on Bempedoic Acid as a therapeutic option for patients needing alternatives to statins [1][2] Group 1: Presentation Details - The first presentation will analyze the incidence of stroke among statin-intolerant patients based on the CLEAR Outcomes trial, scheduled for March 28, 2026 [3] - The second presentation will focus on cardiovascular outcomes in patients with autoimmune or inflammatory diseases, scheduled for March 29, 2026 [3] Group 2: Company Overview - Esperion Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing innovative therapies for cardiometabolic and rare diseases, leveraging expertise in ACLY biology [4] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels [4] - Esperion has a broad U.S. commercial infrastructure and global approvals in over 40 countries, positioning itself as a partner-of-choice for global innovators seeking U.S. market access [5]